• Issue

    Hepatology: Volume 53, Issue 3

    721-1071
    March 2011
Previous Issue|Next Issue
Export Citation(s)Download PDF(s)

Comments from the Editors

Free Access

“Pardon the interruption”: Comments on the International Liver Cancer Association Fourth Annual Conference, 2010. Is there really no role for liver biopsy interpretation in liver cancer?†

Elizabeth M. Brunt M.D.,  Gregory Gores M.D., 
  • Pages: 721-722
  • First Published: 14 February 2011

Editorials

Free Access

Of mice and men: The nonrandom genomic instability in hepatocarcinogenesis†‡

Diego F. Calvisi MD, 
  • Pages: 723-725
  • First Published: 27 January 2011

Viral Hepatitis

Free Access

Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: An updated meta-analysis†‡§

Zhong-Hua Lin,  Yong-Ning Xin,  Quan-Jiang Dong,  Qing Wang,  Xiang-Jun Jiang,  Shu-Hui Zhan,  Ying Sun,  Shi-Ying Xuan, 
  • Pages: 726-736
  • First Published: 07 December 2010
Free Access

Insurance status and treatment candidacy of hepatitis C patients: Analysis of population-based data from the United States†‡

Maria Stepanova,  Fasiha Kanwal,  Hashem B. El-Serag,  Zobair M. Younossi, 
  • Pages: 737-745
  • First Published: 17 December 2010
Free Access

IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection†

Amir Moghaddam,  Espen Melum,  Nils Reinton,  Helmer Ring-Larsen,  Hans Verbaan,  Kristian Bjøro,  Olav Dalgard, 
  • Pages: 746-754
  • First Published: 12 January 2011
Free Access

In vivo evaluation of the cross-genotype neutralizing activity of polyclonal antibodies against hepatitis C virus†‡

Philip Meuleman,  Jens Bukh,  Lieven Verhoye,  Ali Farhoudi,  Thomas Vanwolleghem,  Richard Y. Wang,  Isabelle Desombere,  Harvey Alter,  Robert H. Purcell,  Geert Leroux-Roels, 
  • Pages: 755-762
  • First Published: 11 January 2011
Free Access

No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus†

Andrea Snow-Lampart,  Brandi Chappell,  Maria Curtis,  Yuao Zhu,  Florence Myrick,  James Schawalder,  Kathryn Kitrinos,  Evguenia S. Svarovskaia,  Michael D. Miller,  Jeff Sorbel,  Jenny Heathcote,  Patrick Marcellin,  Katyna Borroto-Esoda, 
  • Pages: 763-773
  • First Published: 18 November 2010
Free Access

Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure †‡

Hitendra Garg,  Shiv Kumar Sarin,  Manoj Kumar,  Vishal Garg,  Barjesh Chander Sharma,  Ashish Kumar, 
  • Pages: 774-780
  • First Published: 14 December 2010

Free Access

Modeling hepatitis B virus X–induced hepatocellular carcinoma in mice with the sleeping beauty transposon system†

Vincent W. Keng,  Barbara R. Tschida,  Jason B. Bell,  David A. Largaespada, 
  • Pages: 781-790
  • First Published: 24 November 2010

Steatohepatitis/Metabolic Liver Disease

Free Access

Patatin-Like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C†

Luca Valenti,  MariaGrazia Rumi,  Enrico Galmozzi,  Alessio Aghemo,  Benedetta Del Menico,  Stella De Nicola,  Paola Dongiovanni,  Marco Maggioni,  Anna Ludovica Fracanzani,  Raffaela Rametta,  Massimo Colombo,  Silvia Fargion, 
  • Pages: 791-799
  • First Published: 13 December 2010
Free Access

Gender-specific differences in adipose distribution and adipocytokines influence adolescent nonalcoholic fatty liver disease †‡

Oyekoya T. Ayonrinde,  John K. Olynyk,  Lawrence J. Beilin,  Trevor A. Mori,  Craig E. Pennell,  Nicholas de Klerk,  Wendy H. Oddy,  Peter Shipman,  Leon A. Adams, 
  • Pages: 800-809
  • First Published: 06 December 2010
Free Access

Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings†‡

Elizabeth M. Brunt,  David E. Kleiner,  Laura A. Wilson,  Patricia Belt,  Brent A. Neuschwander-Tetri,  for the NASH Clinical Research Network (CRN) , 
  • Pages: 810-820
  • First Published: 13 December 2010
Free Access

Molecular therapy for obesity and diabetes based on a long-term increase in hepatic fatty-acid oxidation †‡

Josep M. Orellana-Gavaldà,  Laura Herrero,  Maria Ida Malandrino,  Astrid Pañeda,  Maria Sol Rodríguez-Peña,  Harald Petry,  Guillermina Asins,  Sander Van Deventer,  Fausto G. Hegardt,  Dolors Serra, 
  • Pages: 821-832
  • First Published: 22 December 2010

Hepatobiliary Malignancies

Free Access

MicroRNA-492 is processed from the keratin 19 gene and up-regulated in metastatic hepatoblastoma†

Julia von Frowein,  Philipp Pagel,  Roland Kappler,  Dietrich von Schweinitz,  Adelbert Roscher,  Irene Schmid, 
  • Pages: 833-842
  • First Published: 13 December 2010
Free Access

Paired box gene 5 is a novel tumor suppressor in hepatocellular carcinoma through interaction with p53 signaling pathway†‡

Weili Liu,  Xiaoxing Li,  Eagle S.H. Chu,  Minnie Y.Y. Go,  Lixia Xu,  Guijun Zhao,  Lili Li,  Ning Dai,  Jianmin Si,  Qian Tao,  Joseph J.Y. Sung,  Jun Yu, 
  • Pages: 843-853
  • First Published: 17 December 2010
Free Access

Up-regulation of the fibroblast growth factor 8 subfamily in human hepatocellular carcinoma for cell survival and neoangiogenesis†‡

Christine Gauglhofer,  Sandra Sagmeister,  Waltraud Schrottmaier,  Carina Fischer,  Chantal Rodgarkia-Dara,  Thomas Mohr,  Stefan Stättner,  Christoph Bichler,  Daniela Kandioler,  Fritz Wrba,  Rolf Schulte-Hermann,  Klaus Holzmann,  Michael Grusch,  Brigitte Marian,  Walter Berger,  Bettina Grasl-Kraupp, 
  • Pages: 854-864
  • First Published: 06 December 2010
Free Access

Enrichment of Nur77 mediated by retinoic acid receptor β leads to apoptosis of human hepatocellular carcinoma cells induced by fenretinide and histone deacetylase inhibitors†‡

Hui Yang,  Qi Zhan,  Yu-Jui Yvonne Wan, 
  • Pages: 865-874
  • First Published: 07 December 2010
Free Access

Bile proteomic profiles differentiate cholangiocarcinoma from primary sclerosing cholangitis and choledocholithiasis†‡§

Tim O. Lankisch,  Jochen Metzger,  Ahmed A. Negm,  Katja Voβkuhl,  Eric Schiffer,  Justyna Siwy,  Tobias J. Weismüller,  Andrea S. Schneider,  Kathrin Thedieck,  Ralf Baumeister,  Petra Zürbig,  Eva M. Weissinger,  Michael P. Manns,  Harald Mischak,  Jochen Wedemeyer, 
  • Pages: 875-884
  • First Published: 07 December 2010
Free Access

Risk assessment of hepatitis B virus–related hepatocellular carcinoma development using liver stiffness measurement (FibroScan)†

Kyu Sik Jung,  Seung Up Kim,  Sang Hoon Ahn,  Young Nyun Park,  Do Young Kim,  Jun Yong Park,  Chae Yoon Chon,  Eun Hee Choi,  Kwang-Hyub Han, 
  • Pages: 885-894
  • First Published: 14 December 2010
Free Access

Evolution of genomic instability in diethylnitrosamine-induced hepatocarcinogenesis in mice†

Kristina Aleksic,  Carolin Lackner,  Jochen B. Geigl,  Martina Schwarz,  Martina Auer,  Peter Ulz,  Maria Fischer,  Zlatko Trajanoski,  Marcus Otte,  Michael R. Speicher, 
  • Pages: 895-904
  • First Published: 17 December 2010

Autoimmune, Cholestatic and Biliary Disease

Free Access

DNA hypomethylation causes bile duct defects in zebrafish and is a distinguishing feature of infantile biliary atresia†‡

Randolph P. Matthews,  Steven F. EauClaire,  Monica Mugnier,  Kristin Lorent,  Shuang Cui,  Megan M. Ross,  Zhe Zhang,  Pierre Russo,  Michael Pack, 
  • Pages: 905-914
  • First Published: 07 December 2010
Free Access

Innate immunity and primary biliary cirrhosis: Activated invariant natural killer T cells exacerbate murine autoimmune cholangitis and fibrosis †‡

Si-Jie Wu,  Yao-Hsu Yang,  Koichi Tsuneyama,  Patrick S.C. Leung,  Petr Illarionov,  M. Eric Gershwin,  Ya-Hui Chuang, 
  • Pages: 915-925
  • First Published: 14 December 2010
Free Access

Early predictors of corticosteroid treatment failure in icteric presentations of autoimmune hepatitis †

Andrew D. Yeoman,  Rachel H. Westbrook,  Yoh Zen,  Paola Maninchedda,  Bernard C. Portmann,  John Devlin,  John G. O'Grady,  Phillip M. Harrison,  Michael A. Heneghan, 
  • Pages: 926-934
  • First Published: 22 December 2010

Liver Failure/Cirrhosis/Portal Hypertension

Free Access

Interleukin-10–mediated heme oxygenase 1–induced underlying mechanism in inflammatory down-regulation by norfloxacin in cirrhosis†‡

Isabel Gómez-Hurtado,  Pedro Zapater,  Pablo Bellot,  Sonia Pascual,  Miguel Pérez-Mateo,  José Such,  Rubén Francés, 
  • Pages: 935-944
  • First Published: 07 December 2010

Liver Injury/Regeneration

Free Access

Concerted action of sulfiredoxin and peroxiredoxin I protects against alcohol-induced oxidative injury in mouse liver†

Soo Han Bae,  Su Haeng Sung,  Eun Jung Cho,  Se Kyoung Lee,  Hye Eun Lee,  Hyun Ae Woo,  Dae-Yeul Yu,  In Sup Kil,  Sue Goo Rhee, 
  • Pages: 945-953
  • First Published: 07 December 2010
Free Access

Loss of histone acetyltransferase cofactor transformation/transcription domain-associated protein impairs liver regeneration after toxic injury†

Vivek Shukla,  Cyrille Cuenin,  Nileshkumar Dubey,  Zdenko Herceg, 
  • Pages: 954-963
  • First Published: 13 December 2010
Free Access

Epithelial cell adhesion molecule (EpCAM) marks hepatocytes newly derived from stem/progenitor cells in humans†‡

So-Mi Yoon,  Domniki Gerasimidou,  Reiichiro Kuwahara,  Prodromos Hytiroglou,  Jeong Eun Yoo,  Young Nyun Park,  Neil D. Theise, 
  • Pages: 964-973
  • First Published: 14 December 2010
Free Access

HepaRG cells: A human model to study mechanisms of acetaminophen hepatotoxicity†‡

Mitchell R. McGill,  Hui-Min Yan,  Anup Ramachandran,  Gordon J. Murray,  Douglas E. Rollins,  Hartmut Jaeschke, 
  • Pages: 974-982
  • First Published: 17 December 2010
Free Access

Septum transversum-derived mesothelium gives rise to hepatic stellate cells and perivascular mesenchymal cells in developing mouse liver†‡

Kinji Asahina,  Bin Zhou,  William T. Pu,  Hidekazu Tsukamoto, 
  • Pages: 983-995
  • First Published: 14 December 2010
Free Access

Overexpression of cholesterol 7α-hydroxylase promotes hepatic bile acid synthesis and secretion and maintains cholesterol homeostasis †‡

Tiangang Li,  Michelle Matozel,  Shannon Boehme,  Bo Kong,  Lisa-Mari Nilsson,  Grace Guo,  Ewa Ellis,  John Y. L. Chiang, 
  • Pages: 996-1006
  • First Published: 14 December 2010

Liver Biology/Pathobiology

Free Access

Hepatic stellate cells regulate immune response by way of induction of myeloid suppressor cells in mice†‡

Hong-Shiue Chou,  Ching-Chuan Hsieh,  Horng-Ren Yang,  Lianfu Wang,  Yusuke Arakawa,  Kathleen Brown,  Qingyu Wu,  Feng Lin,  Marion Peters,  John J. Fung,  Lina Lu,  Shiguang Qian, 
  • Pages: 1007-1019
  • First Published: 10 January 2011

AASLD Practice Guideline

Open Access

Management of hepatocellular carcinoma: An update †‡

Jordi Bruix,  Morris Sherman, 
  • Pages: 1020-1022
  • First Published: 19 January 2011

Review

Free Access

Nuclear receptors in liver disease †

Martin Wagner,  Gernot Zollner,  Michael Trauner, 
  • Pages: 1023-1034
  • First Published: 12 January 2011
Free Access

Human hepatic stem cell and maturational liver lineage biology †

Rachael Turner,  Oswaldo Lozoya,  Yunfang Wang,  Vincenzo Cardinale,  Eugenio Gaudio,  Gianfranco Alpini,  Gemma Mendel,  Eliane Wauthier,  Claire Barbier,  Domenico Alvaro,  Lola M. Reid, 
  • Pages: 1035-1045
  • First Published: 12 January 2011

Hepatology Elsewhere

Free Access

Triglyceride synthesis and hepatitis C virus production: Identification of a novel host factor as antiviral target†‡

Catherine Schuster Ph.D.,  Mathieu Lefèvre Ph.D.,  Thomas F. Baumert Ph.D., 
  • Pages: 1046-1048
  • First Published: 11 January 2011
Free Access

Questioning the challenging role of epithelial-to-mesenchymal transition in liver injury†

David Scholten,  Ralf Weiskirchen, 
  • Pages: 1049-1051
  • First Published: 03 March 2011

Image of the Month

Free Access

Congenital portal venous system aneurysms associated with caput medusae†

Tao Li M.D.,  Xu-Ting Zhi M.D.,  San-Yuan Hu M.D., 
  • Pages: 1052-1053
  • First Published: 19 November 2010

Correspondence

Free Access

Further analysis is required to identify an early stopping rule for peginterferon therapy that is valid for all hepatitis B e antigen–positive patients †‡§

Teerha Piratvisuth M.D.,  Patrick Marcellin M.D., 
  • Pages: 1054-1055
  • First Published: 22 December 2010
Free Access

Reply†

Milan J. Sonneveld,  Vincent Rijckborst,  Harry L.A. Janssen, 
  • Page: 1055
  • First Published: 10 January 2011
Free Access

Optimal duration of treatment for acute hepatitis c in human immunodeficiency virus–positive individuals?†

Gail V. Matthews MBChB (UK) PhD,  Gregory J. Dore MD PhD, 
  • Pages: 1055-1056
  • First Published: 12 January 2011
Free Access

Reply†

Lionel Piroth,  Christine Larsen,  Elisabeth Delarocque-Astagneau,  Stanislas Pol, 
  • Pages: 1056-1057
  • First Published: 10 January 2011
Free Access

The wide spectrum of hepatic iron overload†

Melania Manco M.D., Ph.D., F.A.C.N.,  Anna Alisi Ph.D.,  Antonella Mosca M.D.,  Valerio Nobili M.D., 
  • Pages: 1057-1058
  • First Published: 11 January 2011
Free Access

Reply†

James Nelson Ph.D.,  Kris Kowdley M.D., 
  • Pages: 1058-1059
  • First Published: 10 January 2011
Free Access

Treatment of hepatic encephalopathy with rifaximin: More to think about†

Norman Gitlin M.D., 
  • Page: 1059
  • First Published: 14 December 2010
Free Access

Reply†

Jasmohan S. Bajaj M.D.,  Oliviero Riggio M.D., 
  • Pages: 1059-1060
  • First Published: 12 January 2011
Free Access

Alpha-fetoprotein should be included in the hepatocellular carcinoma surveillance guidelines of the american association for the study of liver diseases†

Marrero Jorge A. M.D., M.S.,  El- Serag Hashem B. M.D., M.P.H., 
  • Pages: 1060-1061
  • First Published: 11 October 2010
Free Access

Reply†

Morris Sherman M.D.,  Jordi Bruix M.D., 
  • Pages: 1061-1062
  • First Published: 11 February 2011
Free Access

Meta-analysis using individual participant data is the gold standard for diagnostic studies†

Ming-Hua Zheng M.D.,  Ke-Qing Shi M.D.,  Yu-Chen Fan M.D.,  Yong-Ping Chen M.D., 
  • Pages: 1062-1063
  • First Published: 12 January 2011
Free Access

Reply†

Yong-Ning Xin M.D.,  Zhong-Hua Lin M.D.,  An-Jin Chen M.D.,  Shi-Ying Xuan M.D., 
  • Pages: 1062-1063
  • First Published: 10 February 2011
Free Access

Noncirrhotic presinusoidal portal hypertension is common in cystic fibrosis–associated liver disease†

Peter Witters M.D., Ph.D.,  Louis Libbrecht M.D., Ph.D.,  Tania Roskams M.D., Ph.D.,  Kris De Boeck,  Lieven Dupont,  Marijke Proesmans M.D., Ph.D.,  François Vermeulen M.D.,  Birgitta Strandvik,  Anders Lindblad M.D.,  Xavier Stéphenne,  Etienne Sokal M.D., Ph.D.,  Serge Gosseye M.D.,  Sam Heye,  Geert Maleux,  Raymond Aerts Ph.D.,  Diethard Monbaliu M.D.,  Jacques Pirenne M.D., Ph.D.,  Ilse Hoffman,  Frederik Nevens M.D.,  David Cassiman M.D., Ph.D., 
  • Pages: 1064-1065
  • First Published: 10 January 2011
Free Access

Cystic fibrosis—cirrhosis, portal hypertension, and liver biopsy: Reply†

Peter J. Lewindon F.R.A.C.P.,  Grant A. Ramm Ph.D., 
  • Pages: 1065-1066
  • First Published: 31 January 2011
Free Access

Genotype 4 hepatitis C virus: Beware of false-negative RNA detection†

Sepideh Akhavan M.D.,  Christophe Ronsin M.D.,  Syria Laperche M.D.,  Vincent Thibault M.D., 
  • Pages: 1066-1067
  • First Published: 10 September 2010
Free Access

On the mechanism of action of vitamin E for nonalcoholic steatohepatitis†

Hong-Fang Ji Ph.D,  Liang Shen Ph.D, 
  • Page: 1067
  • First Published: 01 September 2010
Free Access

Early determination of hepatitis C virus RNA may help to decide the duration of therapy for chronic hepatitis C virus genotype 2/3 infection†

Martin Lagging M.D.,  Åsa Alsiö M.D.,  Nina Langeland M.D.,  Court Pedersen M.D.,  Martti Färkkilä M.D.,  Mads Rauning Buhl M.D.,  Kristine Mørch M.D.,  Kristoffer Hellstrand M.D.,  Gunnar Norkrans M.D., 
  • Pages: 1067-1068
  • First Published: 07 September 2010
Free Access

Effects of beta-blockers on survival for patients with cirrhosis and refractory ascites†

Gin-Ho Lo M.D., 
  • Pages: 1068-1069
  • First Published: 22 December 2010
Free Access

Activation of the endotoxin/toll-like receptor 4 pathway: The way to go from nonalcoholic steatohepatitis up to hepatocellular carcinoma†

Anna Alisi Ph.D,  Nadia Panera,  Clara Balsano M.D,  Valerio Nobili M.D, 
  • Page: 1069
  • First Published: 24 September 2010
Free Access

Necrosis versus apoptosis in acetaminophen-induced hepatotoxicity†

Klaus Schulze- Osthoff M.D,  Heike Bantel M.D, 
  • Page: 1070
  • First Published: 06 October 2010
Free Access

Is achievement of sustained virologic response an independent predictor or a cofactor for the development of esophageal varices?†

Li-Ping Ye M.D.,  Xin-Li Mao M.D., 
  • Pages: 1070-1071
  • First Published: 06 October 2010